In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus
(HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently …

HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although
HBV infection can be efficiently prevented by vaccination, and treatments are available, to …

Hepatitis B virus (HBV) infection remains a global public health problem with changing
epidemiology due to several factors including vaccination policies and migration. This …

Background & Aims Risk scores for hepatocellular carcinoma (HCC) developed in Asians
offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This …

Background & Aims A recent consensus document has defined metabolic dysfunction-
associated fatty liver disease (MAFLD) as hepatic steatosis together with overweight …

Background & Aims Several models have recently been developed to predict risk of
hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Our aims were to …

Background & Aims Current guidelines recommend biannual surveillance for hepatocellular
carcinoma (HCC) in all patients with cirrhosis, regardless of etiology. However, HCC …

Abstract Background & Aims Oral antiviral therapy may reduce the disease progression of
chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long‐term …

BACKGROUND Efficacy trials have shown that antiviral therapy improves the outcomes of
patients with chronic hepatitis B virus (HBV) infection. However, prospective data regarding …

Chronic hepatitis B virus (HBV) infection remains a global problem. Several HBV genotypes
exist with different biology and geographical prevalence. Whilst the future aim of HBV …